Fund Of The Week quizzes fund managers about how they’re investing your money. If you’d like to suggest which funds you want ...
In the face of looming revenue decline from blood cancer medication Revlimid, Indian pharma companies Natco Pharma and Dr.
15h
24/7 Wall St. on MSNVEA vs VWO: Which International Vanguard ETF Is Worth Owning?After President Donald Trump’s November 2024 election victory, the Financial Times had reported $140 billion new investment into US equity funds in just the first month. While there is certainly cause ...
Bullish option flow detected in Novo Nordisk (NVO) with 21,940 calls trading, 1.5x expected, and implied vol increasing almost 3 points to ...
A 52-year-old man has knocked his decade-long cocaine addiction on the head after receiving weight-loss injections. The jab ...
As the demand for GLP-1 weight loss medications such as Ozempic, Wegovy, and Zepbound continues to skyrocket, new survey results from 9amHealth reveal that access to these medications has become a ...
MarketBeat on MSN20h
These 3 Stocks Just Announced Major Dividend HikesThese three stocks just announced significant quarterly dividend increases that they are set to pay out soon. While they all ...
The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...
There's a boom in the use of weight loss medications with more new ones on their way, but they are recommended only for the clinically obese. A slew of new weight loss drugs are being tested in 2025.
RANI READ THE FULL RANI RESEARCH REPORT On February 5 th , Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of ...
Shares of direct-to-consumer telehealth platform Hims & Hers Health (NYSE: HIMS) have become a runaway freight train. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results